Ensign Peak Advisors’s Phathom Pharmaceuticals PHAT Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $24.2M | Buy |
2,519,972
+5,688
| +0.2% | +$54.5K | 0.04% | 284 |
|
|
2025
Q1 | $15.8M | Sell |
2,514,284
-12,770
| -0.5% | -$80.1K | 0.03% | 350 |
|
|
2024
Q4 | $20.5M | Sell |
2,527,054
-54,334
| -2% | -$441K | 0.04% | 317 |
|
|
2024
Q3 | $46.7M | Buy |
2,581,388
+336,560
| +15% | +$6.09M | 0.08% | 194 |
|
|
2024
Q2 | $23.1M | Sell |
2,244,828
-35,172
| -2% | -$362K | 0.04% | 293 |
|
|
2024
Q1 | $24.2M | Hold |
2,280,000
| – | – | 0.04% | 290 |
|
|
2023
Q4 | $20.8M | Buy |
2,280,000
+547,828
| +32% | +$5M | 0.04% | 292 |
|
|
2023
Q3 | $18M | Sell |
1,732,172
-24,955
| -1% | -$259K | 0.04% | 284 |
|
|
2023
Q2 | $25.2M | Sell |
1,757,127
-4,064
| -0.2% | -$58.2K | 0.05% | 259 |
|
|
2023
Q1 | $12.6M | Hold |
1,761,191
| – | – | 0.03% | 363 |
|
|
2022
Q4 | $19.8M | Hold |
1,761,191
| – | – | 0.04% | 294 |
|
|
2022
Q3 | $19.5M | Buy |
1,761,191
+85,703
| +5% | +$950K | 0.05% | 276 |
|
|
2022
Q2 | $14.1M | Buy |
1,675,488
+570,729
| +52% | +$4.82M | 0.03% | 321 |
|
|
2022
Q1 | $15M | Sell |
1,104,759
-210,958
| -16% | -$2.87M | 0.03% | 341 |
|
|
2021
Q4 | $25.9M | Buy |
1,315,717
+145,493
| +12% | +$2.86M | 0.05% | 274 |
|
|
2021
Q3 | $37.6M | Sell |
1,170,224
-49,786
| -4% | -$1.6M | 0.08% | 209 |
|
|
2021
Q2 | $41.3M | Sell |
1,220,010
-19,452
| -2% | -$658K | 0.08% | 203 |
|
|
2021
Q1 | $46.6M | Buy |
1,239,462
+14,910
| +1% | +$560K | 0.1% | 178 |
|
|
2020
Q4 | $40.7M | Buy |
1,224,552
+331,760
| +37% | +$11M | 0.09% | 189 |
|
|
2020
Q3 | $32.7M | Buy |
892,792
+42,789
| +5% | +$1.57M | 0.08% | 205 |
|
|
2020
Q2 | $28M | Buy |
850,003
+252,511
| +42% | +$8.31M | 0.08% | 224 |
|
|
2020
Q1 | $15.4M | Sell |
597,492
-19,365
| -3% | -$500K | 0.05% | 275 |
|
|
2019
Q4 | $19.2M | Buy |
+616,857
| New | +$19.2M | 0.05% | 298 |
|